---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-085641"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T21:00:38.230541+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Emmaus Life Sciences board changes: George Sekulich resigns, Jon Kuwahara appointed

## Summary
- George Sekulich resigned from board on Sep 30, 2024, after his termination as Chief Commercial Officer on Oct 4.
- Jon Kuwahara appointed to fill vacancy effective Oct 1, 2024; also named Chair of Audit Committee.
- Kuwahara served as Emmaus director from Jan 2016 to Sep 2018; now VP-Finance at Crinetics Pharmaceuticals (CRNX).
- No family relationships or transactions requiring disclosure under Item 404(a) exist.
- Kuwahara is a CPA with a BBA from University of Hawaii; prior roles at Novus Therapeutics and other life sciences firms.

## SEC filing metadata
- accession: 0001213900-24-085641
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/0001213900-24-085641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/ea0216701-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-085641
- JSON: https://secwatch.observer/filing/0001213900-24-085641.json
- Plain text: https://secwatch.observer/filing/0001213900-24-085641.txt

## Key facts
- Executive change
  Jon Kuwahara was appointed as Director and Chair of Audit Committee at Emmaus Life Sciences, Inc..
  - Action: appointed
  - Role: Director and Chair of Audit Committee
  source text: the Board appointed Jon Kuwahara to fill the resulting vacancy on the Board of Directors. The Board also appointed Mr. Kuwahara to serve as the Chair of the two-person Audit Committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/0001213900-24-085641-index.htm
- Executive change
  George Sekulich resigned as Director at Emmaus Life Sciences, Inc..
  - Action: resigned
  - Role: Director
  source text: On September 30, 2024, George Sekulich resigned as a member of the Board of Directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/0001213900-24-085641-index.htm
- Executive change
  George Sekulich was terminated as Chief Commercial Officer at Emmaus Life Sciences, Inc..
  - Action: terminated
  - Role: Chief Commercial Officer
  source text: in connection with the termination of his employment as our Chief Commercial Officer on October 4, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/822370/000121390024085641/0001213900-24-085641-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.